Breast Cancer Research and Treatment

, Volume 99, Issue 2, pp 177–184

A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer


  • Cari J. McDonald
    • Molecular Medicine ProgramMayo Clinic
  • Charles Erlichman
    • Division of Medical OncologyMayo Clinic
  • James N. Ingle
    • Division of Medical OncologyMayo Clinic
  • Gabriela A. Rosales
    • Department of StatisticsMayo Clinic
  • Cory  Allen
    • Molecular Medicine ProgramMayo Clinic
  • Suzanne M. Greiner
    • Molecular Medicine ProgramMayo Clinic
  • Mary E. Harvey
    • Molecular Medicine ProgramMayo Clinic
  • Paula J. Zollman
    • Molecular Medicine ProgramMayo Clinic
  • Stephen J. Russell
    • Molecular Medicine ProgramMayo Clinic
    • Molecular Medicine ProgramMayo Clinic
    • Division of Medical OncologyMayo Clinic
    • Mayo Clinic
Preclinical investigation

DOI: 10.1007/s10549-006-9200-5

Cite this article as:
McDonald, C.J., Erlichman, C., Ingle, J.N. et al. Breast Cancer Res Treat (2006) 99: 177. doi:10.1007/s10549-006-9200-5


Breast cancer is the most common malignancy and the second leading cause of female cancer mortality in the United States. There is an urgent need for development of novel therapeutic approaches. In this study, we investigated the antitumor potential of a novel viral agent, an attenuated strain of measles virus deriving from the Edmonston vaccine lineage, genetically engineered to produce carcinoembryonic antigen (CEA) against breast cancer. CEA production as the virus replicates can serve as a marker of viral gene expression. Infection of a variety of breast cancer cell lines including MDA-MB-231, MCF7 and SkBr3 at different multiplicities of infection (MOIs) from 0.1 to 10 resulted in significant cytopathic effect consisting of extensive syncytia formation and massive cell death at 72–96 h from infection. All breast cancer lines overexpressed the measles virus receptor CD46 and supported robust viral replication, which correlated with CEA production. TUNEL assays indicated an apoptotic mechanism of syncytial death. The efficacy of this approach in vivo was examined in a subcutaneous Balb C/nude mouse model of MDA-MB-231 cells. Intravenous administration of MV-CEA at a total dose of 1.2×107 TCID50 resulted in statistically significant tumor growth delay ( p=0.005) and prolongation of survival ( p=0.001). In summary, MV-CEA has potent antitumor activity against breast cancer lines and xenografts. Monitoring marker peptide levels in the serum could serve as a low-risk method of detecting viral gene expression during treatment and could allow dose optimization and individualization of treatment. Trackable measles virus derivatives merit further exploration in breast cancer treatment.


breast cancerCEAmeasles virusMV-CEAvirotherapy
Download to read the full article text

Copyright information

© Springer Science+Business Media, Inc. 2006